CAM
JBIO

Cormorant Asset Management’s Jade Biosciences JBIO Stock Holding History

Cormorant Asset Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,566
Closed -$31.6M – 54
2024
Q1 		$31.6M Sell
30,566
-4,054
-12% -$3.1M 1.39% 22
2023
Q4 		$27.4M Sell
34,620
-10,000
-22% -$5.1M 1.31% 22
2023
Q3 		$21.2M Hold
44,620
– – 1.24% 22
2023
Q2 		$26.8M Hold
44,620
– – 1.5% 19
2023
Q1 		$31.5M Sell
44,620
-11,298
-20% -$9.37M 2.07% 14
2022
Q4 		$57.3M Sell
55,918
-10,673
-16% -$7.75M 3.84% 6
2022
Q3 		$38.6M Buy
66,591
+17,143
+35% +$11.4M 2.7% 10
2022
Q2 		$27.1M Sell
49,448
-2,857
-5% -$1.36M 2.05% 17
2022
Q1 		$33.6M Hold
52,305
– – 2.58% 13
2021
Q4 		$21.6M Sell
52,305
-5,715
-10% -$2.89M 1.28% 24
2021
Q3 		$42M Hold
58,020
– – 1.71% 17
2021
Q2 		$44.6M Buy
+58,020
New +$46.4M 1.52% 20

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Cormorant Asset Management's JBIO Position: Q2 2024 in Review

Cormorant Asset Management sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 30,566 shares — an estimated $31.6M sold.

Cormorant Asset Management first reported a position in JBIO in Q2 2021 and held it in 12 quarters. The position peaked at $57.3M in Q4 2022. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Cormorant Asset Management reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 30,566 Jade Biosciences shares in Q2 2024, an estimated $31.6M.
  • Cormorant Asset Management first reported a position in Jade Biosciences in Q2 2021 and held it in 12 quarters.
  • Cormorant Asset Management's Jade Biosciences position peaked at $57.3M in Q4 2022.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.